Scoop: No­var­tis’ re­treat on CAR-T in­cludes ax­ing most of its se­nior ex­ecs on the team

Us­man “Oz” Azam

No­var­tis’ plan to pull back on CAR-T in­cludes purg­ing most of the se­nior ex­ecs in­volved in the project, sig­nal­ing the phar­ma gi­ant’s R&D re­treat is more ex­ten­sive than the com­pa­ny has want­ed to ad­mit so far.

End­points News, which broke the sto­ry on No­var­tis’ sur­pris­ing R&D move, ini­tial­ly ob­tained the top frag­ment of an in­ter­nal cor­po­rate memo au­thored by Us­man “Oz” Azam at No­var­tis spelling out that the com­pa­ny is dis­solv­ing its cell and gene ther­a­py unit re­spon­si­ble for its pi­o­neer­ing work on CAR-T. Now we have the rest of it, and it in­cludes this on the team ex­ecs:

Un­for­tu­nate­ly a num­ber of col­leagues will be im­pact­ed by this change as many po­si­tions are be­ing elim­i­nat­ed. Im­pact­ed US-based as­so­ciates are be­ing no­ti­fied in meet­ings to­day. As­so­ci­ates based in Basel will learn more about their in­di­vid­ual cir­cum­stances on Thurs­day. The ma­jor­i­ty of the CG­TU Lead­er­ship Team mem­bers, who are among the best I have worked with, are al­so im­pact­ed.

Ear­li­er in the week, No­var­tis por­trayed the de­ci­sion to in­te­grate the unit in­to its on­col­o­gy di­vi­sion as an ef­fi­cien­cy move, some­thing No­var­tis does on a reg­u­lar ba­sis. The com­pa­ny, a spokesper­son not­ed, would con­tin­ue to work in the field and “with a new in­te­grat­ed de­vel­op­ment mod­el, we can ef­fi­cient­ly ad­vance our work on CART as part of our fo­cus in im­muno-on­col­o­gy by rein­te­grat­ing the func­tions.”

Elim­i­nat­ing the ex­ec­u­tive team un­der­scores con­cerns that No­var­tis, one of the three key lead­ers in CAR-T, along with Kite and Juno, is step­ping away just as the first CAR-T ther­a­pies are near­ing ap­proval. And No­var­tis has said that it will con­tin­ue to push its lead pro­gram CTL019 in pe­di­atric r/r ALL to the FDA in ear­ly 2017 and the EMA lat­er in 2017.

Just two years ago, in a Forbes cov­er sto­ry, No­var­tis CEO Joe Jimenez vowed to pur­sue CAR-T with a no-ex­pens­es-spared ap­proach to cur­ing can­cer. But how se­ri­ous can it be about CAR-T when the se­nior team lead­ers are be­ing axed as part of a move to elim­i­nate 120 jobs out of the 400 af­fect­ed?

I asked No­var­tis rep­re­sen­ta­tives that ques­tion ear­ly Fri­day, but have yet to hear back. (Up­date: Here’s their re­sponse.)

Azam goes on at one point to as­sure the 400-mem­ber group, many of whom were about to be axed, that “We have led the in­dus­try in trans­form­ing the prac­tice of med­i­cine with CART ther­a­py…the clin­i­cal and reg­u­la­to­ry teams will move to Glob­al Drug De­vel­op­ment and specif­i­cal­ly On­col­o­gy Glob­al De­vel­op­ment, and our col­leagues who are sup­port­ing com­mer­cial readi­ness will move to the On­col­o­gy or­ga­ni­za­tion.”

Here is the en­tire memo ob­tained by End­points:

Dear Col­leagues,

I still vivid­ly re­mem­ber the mo­ment that David Ep­stein in­vit­ed me to lead a new Unit ded­i­cat­ed to Cell & Gene Ther­a­pies. It was a mix­ture of ex­cite­ment and fear – a feel­ing that fu­els my en­tre­pre­neur­ial spir­it, and one that so many of you share. The risk of em­bark­ing on a new ad­ven­ture in un­chart­ed ter­ri­to­ry is that things don’t al­ways work out how you en­vi­sioned. To­day, I have the un­for­tu­nate task of an­nounc­ing that we are dis­solv­ing the Cell & Gene Ther­a­pies Unit. The ad­ven­ture start­ed years ago with the ini­ti­a­tion of the Penn col­lab­o­ra­tion. Af­ter rec­og­niz­ing the unique­ness of this ther­a­py, the or­ga­ni­za­tion im­ple­ment­ed our CG­TU de­sign struc­ture to bring to­geth­er bright minds in dis­parate func­tions from across No­var­tis to act as a SWAT team and fig­ure out how to make this a suc­cess. And we did. In the space of two years we com­plet­ed an un­prece­dent­ed tech trans­fer of CAR tech­nol­o­gy to a com­mer­cial-grade, GMP qual­i­ty, scal­able man­u­fac­tur­ing site in Mor­ris Plains, gained clar­i­ty on the in­di­ca­tions with the great­est ben­e­fit/risk pro­file, ini­ti­at­ed and ful­ly en­rolled two glob­al mul­ti-site clin­i­cal tri­als in two dif­fer­ent in­di­ca­tions, and laid the ground­work for the evo­lu­tion of fu­ture cell pro­cess­ing. But most im­por­tant­ly, as Kathy says, we saved the lives of sev­er­al kinder­garten class­es and dozens of par­ents and grand­par­ents.

We have led the in­dus­try in trans­form­ing the prac­tice of med­i­cine with CART ther­a­py.

While we were fo­cused on cell and gene ther­a­pies, the larg­er No­var­tis or­ga­ni­za­tion con­tin­ued to evolve. We el­e­vat­ed the role of On­col­o­gy, we have in­te­grat­ed our glob­al de­vel­op­ment func­tion, and we are op­er­at­ing, more than ever, as one No­var­tis. This is the time to re-in­te­grate the Unit back to the func­tions. We have grown, the or­ga­ni­za­tion has grown, and it’s time to come back to­geth­er. An in­te­grat­ed Mor­ris Plains foot­print in­clud­ing Tech Ops, Qual­i­ty and IT process de­vel­op­ment will move un­der BT­DM, the clin­i­cal and reg­u­la­to­ry teams will move to Glob­al Drug De­vel­op­ment and specif­i­cal­ly On­col­o­gy Glob­al De­vel­op­ment, and our col­leagues who are sup­port­ing com­mer­cial readi­ness will move to the On­col­o­gy or­ga­ni­za­tion.

Un­for­tu­nate­ly a num­ber of col­leagues will be im­pact­ed by this change as many po­si­tions are be­ing elim­i­nat­ed. Im­pact­ed US-based as­so­ciates are be­ing no­ti­fied in meet­ings to­day. As­so­ci­ates based in Basel will learn more about their in­di­vid­ual cir­cum­stances on Thurs­day. The ma­jor­i­ty of the CG­TU Lead­er­ship Team mem­bers, who are among the best I have worked with, are al­so im­pact­ed.

I know this news may be dif­fi­cult, and I know you have ques­tions. I would like to elab­o­rate on what I have shared here in a Town Hall this af­ter­noon at 15:00 CET/3:00 PM EDT. I know this is short no­tice, so we have arranged many ways for you to con­nect from mul­ti­ple time zones. We have booked rooms in East Hanover, Mor­ris Plains (where I will be) and Cam­bridge, or you can di­al in via We­b­cast or tele­con­fer­ence if you would like to hear more. A meet­ing in­vi­ta­tion will fol­low.

Mi­no­ryx and Sper­o­genix ink an ex­clu­sive li­cense agree­ment to de­vel­op and com­mer­cial­ize lerigli­ta­zone in Chi­na

September 23, 2020 – Hong Kong, Beijing, Shanghai (China) and Mataró, Barcelona (Spain)  

Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales 

Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition

President Trump walks past HHS secretary Alex Azar (Getty Images)

Azar falls in line un­der Trump again. Ex­perts say he's re­in­forc­ing a dark sig­nal sent to the FDA

In the latest incident where Alex Azar has steadfastly taken the side of President Donald Trump over that of the FDA, the HHS secretary was noncommittal this morning when asked if he supports the attempt by his subordinates at the FDA to strengthen guidelines for a vaccine EUA.

Appearing on NBC’s Today Show, the HHS secretary muddied the waters, stating that the guidance that matters is the one that is “actually already out there.”

Vas Narasimhan (AP Images)

UP­DAT­ED: Still held down by clin­i­cal hold, No­var­tis' Zol­gens­ma falls fur­ther be­hind Bio­gen and Roche as FDA asks for a new piv­otal study

Last October, the FDA slowed down Novartis’ quest to extend its gene therapy to older spinal muscular atrophy patients by slapping a partial hold on intrathecal administration. Almost a year later, the hold is still there, and regulators are adding another hurdle required for regulatory submission: a new pivotal confirmatory study.

The new requirement — which departs significantly from Novartis’ prior expectations — will likely stretch the path to registration beyond 2021, when analysts were expecting a BLA submission. That could mean more time for Biogen to reap Spinraza revenues and Roche to ramp up sales of Evrysdi in the absence of a rival.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

New York governor Andrew Cuomo (AP Images)

An­drew Cuo­mo says New York will un­der­take its own vac­cine re­view process, and wouldn’t rec­om­mend trust­ing the fed­er­al gov­ern­ment

The concerns keep mounting over President Donald Trump’s politicization of the FDA and other federal agencies guiding the development of a safe and effective vaccine. And today, the telegenic New York governor Andrew Cuomo appeared to introduce even more politics into the matter — latest in an ongoing series of incidents that have cast the proudly independent FDA in starkly political terms.

During his daily press conference Cuomo said that the state will review any coronavirus vaccines approved by the federal government, citing a lack of trust of the Trump administration. The announcement comes one day after Trump accused the FDA of making an “extremely political” move in proposing stricter vaccine guidance.

Laura Shawver (Silverback Therapeutics)

Fol­low­ing a hefty Se­ries B, Sil­ver­back Ther­a­peu­tics quick­ly pulls in $85M for 'an im­por­tant growth phase'

Months after reeling in a $78 million Series B round, Silverback Therapeutics has hooked an even larger Series C.

The Seattle-based company announced Wednesday that it netted $85 million from a slate of new and previous investors. The quick boost could be a sign that an IPO is on the way.

In an email, Silverback CEO Laura Shawver told me she was “not able to provide any additional comments about Silverback” beyond what was shared in the company’s news release. In the prepared statement, she said the company is at “an important growth phase.”

Covid-19 roundup: Op­er­a­tion Warp Speed's 7th vac­cine is live at­ten­u­at­ed; Small biotech touts big suc­cess where gi­ants have failed

Operation Warp Speed is stacking its vaccine portfolio with a “TBD” new candidate: a live attenuated vaccine that can be administered in a single dose, potentially as an oral formulation rather than an injection.

Sound familiar?

That could be because the unannounced candidate appears to match the profile of an inoculation being developed by Merck, according to Bloomberg, which first reported the development based on a presentation by Moncef Slaoui.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

PhII Alzheimer's fail­ure deals new blow to Roche, AC Im­mune — but the tau hy­poth­e­sis is far from dead

The leading anti-tau antibody has failed its first Phase II testing, casting a shadow on a popular target (just trailing amyloid beta) for Alzheimer’s disease.

Roche and AC Immune are quick to acknowledge disappointment in the topline readout, which suggested that semorinemab did not reduce cognitive decline among patients with early Alzheimer’s disease, who are either just starting to have symptoms or have mild manifestations.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

On­ly five months af­ter a Se­ries A launch, Taysha goes pub­lic with $157M IPO

As has been the trend in 2020, Taysha Gene Therapies has become the latest biotech to make a quick ascent from a small, privately-funded company to enjoying its very own Nasdaq ticker.

The Dallas-based biotech raised $157 million for its IPO after pricing shares at $20 apiece Thursday, the high-point of its expected range. Initially pegging $100 million in financing, Taysha offered a little less than 8 million shares and will trade under the $TSHA symbol.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

CDC’s Robert Redfield, NIAID’s Anthony Fauci, Admiral Brett Giroir at HHS, and FDA’s Stephen Hahn prepare to testify at a House hearing on June 23 (Getty)

'Ex­treme­ly po­lit­i­cal' — Trump neuters FDA's at­tempt to strength­en vac­cine EUA

Stephen Hahn went before a Senate committee Wednesday and declared he’s fighting. “Every one of the decisions we have reached has been made by career FDA scientists based on science and data, not politics,” he exclaimed, adding that “FDA will not permit any pressure from anyone to change that. I will fight for science.”

A few hours later, he was undermined by President Donald Trump when a reporter asked if he was okay with stricter vaccine guidelines that the FDA was said to be cooking up. “That has to be approved by the White House. We may or may not approve it. That sounds like a political move,” he decided.